Type 2 diabetes: cost-effectiveness of medication adherence and lifestyle interventions

Tomaž Nerat
Igor Locatelli
Mitja Kos
Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia

Introduction: Type 2 diabetes is a major burden for the payer, however, with proper medication adherence, diet and exercise regime, complication occurrence rates, and consequently costs can be altered.

Aims: The aim of this study was to conduct a cost-effectiveness analysis on real patient data and evaluate which medication adherence or lifestyle intervention is less cost demanding for the payer.

Methods: Medline was searched systematically for published type 2 diabetes interventions regarding medication adherence and lifestyle in order to determine their efficacies, that were then used in the cost-effectiveness analysis. For cost-effectiveness analysis-required disease progression simulation, United Kingdom Prospective Diabetes Study Outcomes model 2.0 and Slovenian type 2 diabetes patient cohort were used. The intervention duration was set to 1, 2, 5, and 10 years. Complications and drug costs in euro (EUR) were based on previously published type 2 diabetes costs from the Health Care payer perspective in Slovenia.

Results: Literature search proved the following interventions to be effective in type 2 diabetes patients: medication adherence, the Mediterranean diet, aerobic, resistance, and combined exercise. The long-term simulation resulted in no payer net savings. The model predicted following quality-adjusted life-years (QALY) gained and incremental costs for QALY gained (EUR/QALYg) after 10 years of intervention: high-efficacy medication adherence (0.245 QALY; 9,984 EUR/QALYg), combined exercise (0.119 QALY; 46,411 EUR/QALYg), low-efficacy medication adherence (0.075 QALY; 30,967 EUR/QALYg), aerobic exercise (0.069 QALY; 80,798 EUR/QALYg), the Mediterranean diet (0.057 QALY; 27,246 EUR/QALYg), and resistance exercise (0.050 QALY; 111,847 EUR/QALYg).

Conclusion: The results suggest that medication adherence intervention is, regarding cost-effectiveness, superior to diet and exercise interventions from the payer perspective. However, the latter could also be utilized by patients without additional costs, but medication adherence intervention requires trained personnel because of its complex structure. Interventions should be performed for >2 years to produce noticeable health/cost results.

Keywords: type 2 diabetes, adherence, intervention, medication, lifestyle, cost-effectiveness

Introduction

Type 2 diabetes is a major health care burden for the payer. In the scope of global estimates, the prevalence will rise and consequently the costs.1,2 The disease incidence, prevalence, progression, and complication occurrence are dependent on a number of factors: weight, fat distribution, fasting glucose, glycated hemoglobin (HbA1c), blood lipids, blood pressure, physical inactivity, family history, race, and age.3 Therefore, accurate drug regime adherence and improved lifestyle regarding diet and exercise are the key to decelerate the disease progression and the incidence...
of complications. As a result, disease costs can be altered. Major trials were performed to assess the impact of lower blood glucose levels, lower blood pressure and lower lipid levels on disease progression and occurrence of microvascular and macrovascular complications. The ACCORD, ADVANCE, and VADT studies focused on single risk factor enhancements (blood glucose and lipid lowering) and concentrated on achieving tight glucose control in a short time. However, primary results have not demonstrated any reduction of complications occurrence or mortality. In ACCORD’s follow-up study, it was revealed that lowering HbA1c to <7% actually reduced the mortality rate. Furthermore, the mortality rate increased linearly from 6% to 9% HbA1c. The positive effect of a lower HbA1c on cardiovascular complications (the United Kingdom Prospective Diabetes Study [UKPDS], HOPE study) was also detected in long-term epidemiological studies. The intervention results in type 2 diabetes patients, however, strongly indicated that all three risk factors (glucose levels, lower blood pressure, and lower levels of cholesterol) should be targeted to achieve optimal diabetes progression reduction and complications occurrence reduction. Consequently, the Steno study was conducted. In the study, HbA1c, total cholesterol, and serum triglycerides were used as primary outcome measures. The results confirmed that type 2 diabetes complication occurrence rate drops were significantly higher than those reported in studies employing single risk factor control interventions, suggesting that with proper multifactorial interventions, diabetes outcomes and payer burden can be altered. As noted previously, interventions regarding medication adherence and lifestyle (diet and exercise) are suitable to alter multiple diabetes risk factors, especially the HbA1c, high-density lipoprotein (HDL), low-density lipoprotein (LDL), weight, and blood pressure values.

The aim of the present study was therefore to conduct a cost-effectiveness analysis on real patient data and evaluate which medication adherence or lifestyle intervention to choose, when to apply it, and which one is less cost demanding for the payer with the help of quality-adjusted life-years (QALYs) gained and cost increment predictions.

**Methods**

To conduct a cost-effectiveness analysis of medication adherence and lifestyle interventions on real patient data, the literature was searched for relevant interventions and their efficacy, eligible simulation software, intervention costs, type 2 diabetes complication costs, and drug costs. The steps taken in the study are detailed as follows.

**Search strategy and study selection for intervention assessment**

Search key (type 2 diabetes) AND (exercise OR workout OR diet OR dietary OR diets OR adherence OR compliance) AND (intervention OR interventions) AND (meta OR review) were used on Medline database to search for possible interventions and their efficacies. Date of publication was not limited. Studies that clearly assessed medication adherence and lifestyle interventions and consequently allowed to quantitatively determine effectiveness of each intervention were included. Studies that encompassed interventions regarding behavior changes for intervention efficacy enhancing, interventions encompassing gestational diabetes, depression, diabetes prevention, risk of diabetes, schizophrenia, children, adolescents, type 1 diabetes, kidney diseases, dialysis, and transplantation were excluded. Based on the written protocol for review, one reviewer assessed titles and abstracts of all the retrieved articles. Abstracts that did not provide enough information regarding the eligibility criteria were retrieved for full-text evaluation. The full-texts of selected articles were also evaluated on the basis of the eligibility criteria. The final selection was checked and discussed with other authors.

**Simulation model used**

The UKPDS Outcomes model 2.0 was used for type 2 diabetes progression simulations. The model predicts future events year by year, based on a series of risk equations, derived from the initial UKPDS cohort. The key aspect of the model is its ability to capture the clustering or interaction of different types of complications at an individual patient level. It also allows modification of various type 2 diabetes risk factor values for any given patient life year. Therefore, the model is suitable for the present cost-effectiveness assessment, as different durations of interventions could be simulated. Regarding the Fifth Mount Hood challenge, the UKPDS Outcomes model performs reasonably well when performing relative risk simulations. In addition, it also predicted higher cardiovascular mortality correctly with relation to aggressive HbA1c and blood pressure control, which the other models did not.

The simulation software allows the use of multiple computer processor cores. However, the results differ slightly regarding the number of cores used. Our calculations were conducted with Xeon 1231v3 processor with seven logical
cores used, the number of loops value was set to 10,000 and
the bootstraps value was set to 999. These settings produced
stable results with a relative error of <5% (obtained from
model results).

The study was performed from the Slovenian Health Care
payer perspective. The latter consists of The Health Insur-
ance Institute of Slovenia as compulsory health insurance
and several complementary insurances. The patients were
followed up for a lifetime. Outcomes were simulated in yearly
cycles and included model-provided QALYs gained and costs
in euros (EUR) as results, with a 5% annual discount rate
for both. The outcomes were expressed as an incremental
cost-effectiveness ratio (ICER) in EUR per QALY gained
(EUR/QALYg) for each intervention type and their duration
compared to no intervention.

Because of different intervention durations, we decided
to simplify and assumed that each intervention lasted 1 year,
although two diet and one exercise interventions were previ-
ously conducted for 2 years and 4 years, respectively.23–25
Therefore, to simulate an intervention effect for multiple
years, the intervention had to be repeated annually. In our case,
simulations were conducted for 1 and 2 years of intervention
duration to capture the effects based on published studies and
for 5 and 10 years to predict the possible effects with longer
intervention duration. A longer intervention inclusion was
possible because duration of intervention was not among
predictors of dropout in long-term disease care program
and short-term interventions according to published data.26–29

Cost-effectiveness of different interventions

Patient data

Individual patient data were obtained in advance from the
Slovenian pharmacist intervention study presented at the
National Diabetes Conference in 2014 where 93 type 2 dia-
abetes patients were recruited.30 The mean (standard deviation)
age of the patients was 65.9 (7.5) years which was therefore
higher than that researched before in Slovenia [59 (10.1)
and 62.2 years]; however, other diabetes risk factors were
comparable.31,32 Average HbA1c values from our cohort were
0.1% higher; HDL 0.03 mmol/L, and LDL 0.61 mmol/L
lower; and systolic blood pressure 2 mmHg higher, and
therefore, despite different average age, the values were gen-
erally similar.31,32 Outcomes model 2.0 is based on new onset
diabetes patients (mean age 53 years) who were followed-up
for 25 years (intervention median of 16.8 and 17.7 years, post-
trial 8.5 and 8.8 years, respectively). Therefore, a simulation
with patients of higher age is possible.33 The heart rate, WBC
count, hemoglobin, and estimated eGFR were not obtained
from the patients, because at the time of the Slovenian inter-
vention study the required input values for UKPDS Outcomes
model 2.0 were not published. Therefore, published mean
values were used and were adjusted to individual patients for
outcomes model internal equations.34–37 Patient demographic
data are presented in the “Results” section.

Costs and utilities of diabetes complications and
medications

Previously published type 2 diabetes costs from the Health
Care payer perspective in Slovenia were used to assess the
cost values of diabetes complications and medication.38
The published costs were valid for the year 2011. Therefore, an
update with recent Health Care payer data was conducted.
All 2015 costs were lower than the 2011 costs, in particular
the medication expenses. The assessed costs for the year
2015 are presented in Table S1. The prices of statins, ACE
inhibitors, beta blocking agents, and acetylsalicylic acid fell
by 60%, 40%, and 20%, respectively, from 2011 to 2014.39
The cost of the antidiabetics and insulin, however, fell only by
6%.40 The medication cost reduction calculation is provided
detail in the Supplementary materials.

For utility decrements, UKPDS Outcomes model 2.0-
published values were used (presented in Table S1).

Intervention costs

Previously published data were used to assess the inter-
vention costs. For the medication adherence intervention,
baseline costs of 329 EUR for 1 year of intervention dura-
tion (currency conversion on March 15, 2016: USD411.5)
were used.40 The costs were further inflated by higher drug
consumption (52 EUR for high-efficacy adherence interven-
tion and 13 EUR for low-efficacy adherence interven-
tion). Higher adherence costs were derived from baseline drug
consumption costs. For the medication adherence intervention,
previously published values were used and were adjusted to individual patients for
outcomes model internal equations.34–37 Patient demographic
data are presented in the “Results” section.

Costs and utilities of diabetes complications and
medications

Previously published type 2 diabetes costs from the Health
Care payer perspective in Slovenia were used to assess the
cost values of diabetes complications and medication.38
The published costs were valid for the year 2011. Therefore, an
update with recent Health Care payer data was conducted.
All 2015 costs were lower than the 2011 costs, in particular
the medication expenses. The assessed costs for the year
2015 are presented in Table S1. The prices of statins, ACE
inhibitors, beta blocking agents, and acetylsalicylic acid fell
by 60%, 40%, and 20%, respectively, from 2011 to 2014.39
The cost of the antidiabetics and insulin, however, fell only by
6%.40 The medication cost reduction calculation is provided
detail in the Supplementary materials.

For utility decrements, UKPDS Outcomes model 2.0-
published values were used (presented in Table S1).

Cost-effectiveness of different interventions

Patient data

Individual patient data were obtained in advance from the
Slovenian pharmacist intervention study presented at the
National Diabetes Conference in 2014 where 93 type 2 dia-
abetes patients were recruited.30 The mean (standard deviation)
age of the patients was 65.9 (7.5) years which was therefore
higher than that researched before in Slovenia [59 (10.1)
and 62.2 years]; however, other diabetes risk factors were
comparable.31,32 Average HbA1c values from our cohort were
0.1% higher; HDL 0.03 mmol/L, and LDL 0.61 mmol/L
lower; and systolic blood pressure 2 mmHg higher, and
therefore, despite different average age, the values were gen-
erally similar.31,32 Outcomes model 2.0 is based on new onset
diabetes patients (mean age 53 years) who were followed-up
for 25 years (intervention median of 16.8 and 17.7 years, post-
trial 8.5 and 8.8 years, respectively). Therefore, a simulation
with patients of higher age is possible.33 The heart rate, WBC
count, hemoglobin, and estimated eGFR were not obtained
from the patients, because at the time of the Slovenian inter-
vention study the required input values for UKPDS Outcomes
model 2.0 were not published. Therefore, published mean
values were used and were adjusted to individual patients for
outcomes model internal equations.34–37 Patient demographic
data are presented in the “Results” section.

Costs and utilities of diabetes complications and
medications

Previously published type 2 diabetes costs from the Health
Care payer perspective in Slovenia were used to assess the
cost values of diabetes complications and medication.38
The published costs were valid for the year 2011. Therefore, an
update with recent Health Care payer data was conducted.
All 2015 costs were lower than the 2011 costs, in particular
the medication expenses. The assessed costs for the year
2015 are presented in Table S1. The prices of statins, ACE
inhibitors, beta blocking agents, and acetylsalicylic acid fell
by 60%, 40%, and 20%, respectively, from 2011 to 2014.39
The cost of the antidiabetics and insulin, however, fell only by
6%.40 The medication cost reduction calculation is provided
detail in the Supplementary materials.

For utility decrements, UKPDS Outcomes model 2.0-
published values were used (presented in Table S1).

Intervention costs

Previously published data were used to assess the inter-
vention costs. For the medication adherence intervention,
baseline costs of 329 EUR for 1 year of intervention dura-
tion (currency conversion on March 15, 2016: USD411.5)
were used.40 The costs were further inflated by higher drug
consumption (52 EUR for high-efficacy adherence interven-
tion and 13 EUR for low-efficacy adherence interven-
tion). Higher adherence costs were derived from baseline drug
consumption costs. For the medication adherence intervention,
previously published values were used and were adjusted to individual patients for
outcomes model internal equations.34–37 Patient demographic
data are presented in the “Results” section.
The 2-year duration was chosen because it is supported by published data, whereas 5- and 10-year intervention durations are predictions.

**Results**

**Description of studies selected for medication adherence and lifestyle intervention cost-effectiveness analysis**

In the initial search on Medline (January 1, 2016), 1,360 potentially relevant citations were retrieved, from which 52 articles were subjected to full-text review after title and abstract screening. After the review, 20 met the inclusion criteria. One of them was attributed to medication adherence, ten to diet lifestyle interventions, and nine to exercise lifestyle interventions. The interventions are presented in detail with a flow diagram in Figure 1.

**Medication adherence interventions**

Retrieved studies encompassed the following intervention subtypes: simplification of drug regimen; patient education and information; intensified patient care, with reminders via mail, telephone, or handheld devices; Internet-based programs; home telehealth devices and also complex behavior approaches with or without group sessions. The duration of the studies ranged from a few weeks to 2 years. Diverse intervention approaches prevented the authors from conducting a meta-analysis. Therefore, highest and lowest ranges of HbA1c reduction (−1.5% to −0.5%) were utilized for the cost-effectiveness analysis. Upper and lower HDL, LDL, blood pressure, and weight changes were derived from reviews that were cross-referenced with the selected articles, by us. In all the interventions, the common factor was that the intervention effects lasted for the duration of the intervention. After cessation, the effects disappeared. It was assumed that the effect disappearance occurs shortly after conclusion of the intervention because after the UKPDS intensive therapy intervention had ended, the between-group difference in glycated hemoglobin was lost in the following year. Different intervention efficacies for HbA1c, LDL, HDL, weight, and blood pressure are summarized in Table 1.

**Diet lifestyle interventions**

Diet interventions were divided into low carbohydrate, high protein, (very) low glycemic index, low-fat, ADA, conventional, the Mediterranean, and vegetarian diets. However, conventional, low-fat, ADA and low glycemic index diets were utilized as reference or control diets. Ajala et al conducted the first meta-analysis of different diets and reported their impact on glycemic control, weight, and blood lipids. The meta-analysis was conducted with

---

**Figure 1** Flow diagram of literature search and study selection.

1,360 articles were identified from database search

52 articles remained after exclusion based on review of title and abstract

32 articles were excluded based on full-text review

16 articles provided intervention description without type 2 diabetes risk factor outcomes
5 articles provided intervention description on macronutrient level, not diet subgroups
5 articles provided interventions to enhance intervention efficacy
2 articles provided overall lifestyle interventions and not divided into subgroups
1 article provided description of one randomized controlled trial
1 article provided description of four short-duration intervention studies
1 article provided intervention description with outcome assessment of different factors than diabetes
1 article provided intervention for diabetes prevention

20 articles met the inclusion criteria
fixed effect model despite high heterogeneity among the included studies. It also encompassed only studies longer than 6 months. The article comment further highlighted that very-low-carbohydrate and high-protein diets are not officially recommended because of their unconfirmed long-term effects. Therefore, these diets were excluded from the cost-effectiveness analysis. Two review articles were published for the low-carbohydrate diet. The included low-carbohydrate studies utilized significantly different dietary interventions (carbohydrate intakes from >20 to 166 g/day) and control diets. No study was conducted with the usual diet control group. Consequently, no clear impact on diabetes risk factors could be established. Since the remaining studies suggested superior effect of the Mediterranean diet, the low-carbohydrate intervention was excluded from the cost-effectiveness analysis. The vegetarian diets were effective in HbA1c reduction; however, the published meta-analysis didn’t present the impact on the remaining diabetes risk factors. Vegetarian diet interventions were compared to meat diets, and none utilized the usual diet as comparison. Consequently, vegetarian diets were excluded from the cost-effectiveness analysis. The Mediterranean diet was the only intervention that was compared to the usual diet. In the Ajala et al study, the Mediterranean diet effect was assessed to lower HbA1c by −0.41%. However, with random effects model utilization instead of the fixed effect, the HbA1c reduction amounted to −0.28% (using RevMan 5). Similar effect was also reported in the Carter et al and the Huo et al meta-analyses (random effects model: −0.31%, −0.30%). All usual diet comparisons were based on the study of Toobert et al which stated a −0.40% HbA1c reduction, despite some publications reporting −0.34%. Since the Huo et al study (nine studies, 1,178 patients) was the latest published, its reported efficacy was used in the cost-effectiveness analysis as the reported efficacy was similar to other studies and it reported the effects on other diabetes risk factors. For the blood pressure diet impact, data from Nordmann et al (six trials, 2,650 patients) were used.

Interventions were applied on different age groups and body mass groups with different comorbidities. Intervention effects disappeared after the study conclusion. As noted previously, the obtained intervention efficacies (average with upper and lower confidence interval [CI] 95% values) on HbA1c, LDL, HDL, weight, and blood pressure are summarized in Table 1.

### Exercise lifestyle interventions

Diabetes patients were generally subjected to aerobic, resistance, and combined exercise interventions. The duration of the intervention session was on average between 30 and 60 minutes, with 2–3 sessions per week and intervention duration of 12 weeks to 2 years. Similarly to diet interventions, the exercise studies were applied to different age groups and body mass groups with different comorbidities. Umpierre et al conducted a meta-analysis to assess the efficacy of aerobic (−0.73% HbA1c), resistance (−0.57%), and combined training (−0.51%). However, the aerobic group included patients with higher baseline HbA1c and with three or more exercise sessions per week which suggested a higher effect. The impact of baseline HbA1c and the number of sessions was afterwards confirmed by Umpierre et al, stating that each additional training day and baseline HbA1c unit resulted in 0.3% lower HbA1c values. Armstrong et al furthermore specified that the combined exercise efficacy was
assessed too low. The latter was confirmed by Hayashino et al, Schwingshackl et al, and Chudyk et al where combined training resulted in highest HbA1c reduction efficacy in comparison with aerobic and resistance training.\textsuperscript{55,58,62}

Hayashino et al and Yang et al published comparable efficacy results for aerobic and resistance training on HbA1c reduction (−0.46% and −0.32%) and Chudyk et al published equivalent results of resistance training (−0.33%).\textsuperscript{55,60,62} However, resistance training should not be conducted with resistance bands alone in order to be effective.\textsuperscript{59} Hayashino et al, Yang et al, and Chudyk et al also published comparable results with exercise interventions on lipid profile.\textsuperscript{55,60,62} The largest difference was observed among intervention effects on blood pressure. Hayashino et al published the lowest efficacy effect, which was followed by Figueira et al and Yang et al.\textsuperscript{55,57,60} For the cost-effectiveness analysis, results from the Hayashino et al (41 included studies, 2,808 patients) meta-analysis were utilized because the study included results for all types of exercise interventions.\textsuperscript{55} Table 1 summarizes different intervention efficacies (average with upper and lower CI 95% values) on HbA1c, LDL, HDL, weight, and blood pressure.

**Cost-effectiveness of different medication adherence and lifestyle interventions**

As mentioned earlier, the analysis was conducted on real patient data. The patient demographic data are presented in Table 2. The quality-adjusted life expectancy for all diabetes patients without intervention was 7.769 QALYs. All interventions demonstrated higher quality-adjusted survival than the base case without intervention. The highest average survival was estimated with medication adherence intervention (high efficacy), followed by combined exercise, medication adherence (low efficacy), aerobic exercise, the Mediterranean diet, and resistance exercise. The first three interventions with 2-year intervention duration performed 0.061, 0.027, and 0.019 better than the base case without intervention and the ones with 10-year intervention duration performed 0.245, 0.119, and 0.075 better, respectively. The total lifetime costs were also higher in all the cases, which resulted in an ICER between 9,984 EUR (medication adherence) and 148,424 EUR (resistance exercise). The simulated ICER values per QALY gained, QALY gained, and cost increments for all interventions and duration are presented in Table 3. In Figure 2 ICER values per QALY gained are presented.

Aerobic and resistance intervention exercises present a concave, ICER per QALY gained, graph. Other interventions with the exception of combined exercise also result in a concave ICER chart which is considerably less curved. The chart shape is the result of higher QALY gained after 2 or 5 years of intervention which is more noticeable in the case of interventions with low performance. The ICER shape is also the outcome of natural deaths, which are correlated with intervention costs. With longer duration of type 2 diabetes, the intervention costs still rise, however, not linearly, and fall more with each year (occurrence of predicted natural deaths) of simulation and consequently the ICER value decreases.

**Sensitivity analysis**

One-way sensitivity analysis varying complication costs, intervention costs, and discount rates showed that the discount rate had the largest impact on the ICER. The impact of intervention costs was also significant, but the impact of complication costs was minimal.

**Discussion**

The results indicate that diabetes medication adherence and lifestyle interventions result in higher quality-adjusted life expectancy. Efficacy and intervention costs are an important factor for intervention cost-effectiveness. Regarding the cost savings aim of the present study, it has to be mentioned that no intervention produced net savings. Therefore, diabetes interventions are effective in the prevention of complications, but not in the reduction of payer burden.

Similar exercise intervention impact was detected previously as well, when the cost-effectiveness of community-based
physical activity interventions was assessed. The published QALY gain of different interventions (medication adherence and lifestyle) ranged from 0.014 to 0.14 QALYs, whereas our simulation results ranged from 0.009 to 0.245 QALY gained.

While comparing medication adherence intervention cost-effectiveness with previously published data of 9,000 EUR/QALYg, it was found that our efficacy, cost, and patient data regarding this particular intervention were correct. A similar intervention was also conducted on Dutch diabetes patients where the intervention cost-effectiveness resulted in ICER of 14,814 EUR/QALYg in patients with history of cardiovascular diseases and in ICER of 38,243 EUR/QALY in all patients, which is higher than our calculated values in the case of high-efficacy intervention but, however, similar to low efficacy medication adherence.

On the subject of exercise interventions, previously published studies reported cost per QALY outcomes of up to 68,557 USD/QALYg. While considering higher intervention costs, the result is similar to our estimated

<table>
<thead>
<tr>
<th>Intervention duration (years)</th>
<th>Estimated QALY gained</th>
<th>Estimated cost increments in EUR</th>
<th>ICER (EUR/QALYg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Medication adherence (high efficacy)</td>
<td>0.033</td>
<td>0.061</td>
<td>0.135</td>
</tr>
<tr>
<td>Medication adherence (low efficacy)</td>
<td>0.015</td>
<td>0.019</td>
<td>0.046</td>
</tr>
<tr>
<td>The Mediterranean diet</td>
<td>0.011</td>
<td>0.014</td>
<td>0.031</td>
</tr>
<tr>
<td>Aerobic exercise</td>
<td>0.011</td>
<td>0.019</td>
<td>0.036</td>
</tr>
<tr>
<td>Resistance exercise</td>
<td>0.009</td>
<td>0.012</td>
<td>0.023</td>
</tr>
<tr>
<td>Combined exercise</td>
<td>0.012</td>
<td>0.027</td>
<td>0.063</td>
</tr>
</tbody>
</table>

**Table 3** Estimated QALYs gained (QALYg) and cost increments (EUR) per each intervention compared to option without the intervention and calculated ICER values.

**Abbreviations:** ICER, incremental cost-effectiveness ratio; QALYS, quality-adjusted life-years.

![Figure 2](https://www.dovepress.com/) Calculated incremental cost-effectiveness ratio ICER (EUR/QALYg) per each intervention compared to option without the intervention.
values in exercise intervention cases (from 46,411 to 86,940 EUR/QALYg, excluding results over 100,000 EUR/QALYg).

While utilizing diabetes-specific nutritional meal replacements as part of the diabetes management program, the outcomes produced an incremental cost-effectiveness output of 47,917 to 50,414 USD/QALYg, whereas our estimated values for diet intervention ranged from 21,653 EUR/QALYg to 31,080 EUR/QALYg.71

Limitations
The present cost-effectiveness diabetes intervention simulation was conducted on real patients. However, the raw data lack values for heart rate, WBC count, hemoglobin, and estimated glomerular filtration rate. Therefore, the simulation could estimate different absolute and possibly smaller relative differences in results. However, with a slight adjustment of average blood risk factor values in individual patients, the possibility of an error was lowered. Complex medication adherence studies also utilized lifestyle counseling among medication adherence education, however, without the usage of any diet and exercise interventions.41

The meta-analyses of different interventions were conducted with different effects. The authors used fixed and random effects, meaning that the results are prone to errors. Furthermore, the authors generally did not explain the reasons why a particular model was used. However, reviews and meta-analyses referenced in Table 1 utilized random effects model for efficacy calculation which was suggested as preferable.63

After 1 year of the UKPDS intervention discontinuation, the between-group differences in diabetes risk factor values were lost; however, the intervention effect persisted.13 This effect was named “memory effect.”13 In our simulation, after the conclusion of the intervention, we utilized diabetes risk factors predicted in the base case, meaning that the intervention trend was stopped and the future memory effect was not present because the UKPDS outcomes model does not utilize equations to compensate for the memory effect. It is therefore possible that longer interventions predicted higher complication outcomes.

Unaltered individual patient data from the pharmacist intervention study were used.30 The results of this intervention study are presented elsewhere.30

Which intervention to choose
While combining the results from high- and low-efficacy medication adherence intervention studies, the QALY and EUR/QALYg benefits exceed other interventions, indicating that medication adherence interventions are superior to diet and exercise interventions. However, when higher adherence results in significantly elevated drug costs or co-payments for the patient, then exercise and diet interventions are also important to consider since the literature suggests that with higher drug costs for the patient the adherence could fall.72

The study was conducted with published intervention costs and an assumption that interventions need to be supervised. Nevertheless, diet and exercise interventions could also be conducted in patients with no supervision. Hypothetically, the patients could follow proper diet and exercise guidelines on the basis of common self-care which would result in no costs for the Heath Care payer. In the case of medication adherence, lack of supervision is not possible because the process consists of various steps (education sessions, drug reminders, blood tests, self-care reminders, and medication dispensing) where trained personnel are needed.

We should also consider that exercise is probably harder to implement in elderly patients. While examining average age in studies included in the Hayashino et al. meta-analysis, most studies included patients <60 years with few carried out on patients >60 years.55 Therefore, it is sensible to implement exercise interventions with younger patients (with low costs), and the diet intervention with the elderly, when medication adherence intervention is not preferred.

The results also indicate that intervention duration ≤2 years results in low ICER values; however, the QALY gained output is also low and similar between all interventions. Consequently, it is reasonable to conduct longer interventions particularly because QALY gains are more noticeable. It is insignificant which duration to choose for combined exercise, the Mediterranean diet, and medication adherence from the ICER standpoint because ICER decreases slightly, whereas for the aerobic and resistance exercise interventions, it is appropriate to choose interventions longer than 5 years because ICER decreases after 5 years of intervention.

Conclusion
The results suggest that from the payer perspective, medication adherence intervention is cost-effective and is superior to diet and exercise interventions. However, the latter could be utilized by patients without additional costs, whereas medication adherence intervention requires trained personnel because of its complex structure. Interventions should be performed for >2 years to produce noticeable health/cost results.
Patient Preference and Adherence downloaded from https://www.dovepress.com/ by 54.70.40.11 on 12-Jul-2019
For personal use only.

Disclose
The authors report no conflicts of interest in this work.

References
Supplementary materials

The following defined daily doses (DDD) and published Health Care payer expenses for different anatomic therapeutic groups (ATC) were utilized for the year 2011 and 2014.1

ATC code C10AA, C10BA; 2011  901,671 DDD/2014  874,060 DDD; 2011  249,911 euro/2014  92,751 euro

ATC code C09A, C09B, C09C; 2011  1,216,343 DDD/2014  960,862 DDD; 2011  53,797 euro/2014  24,804 euro

ATC code C07; 2011  810,770 DDD/2014  772,186 DDD; 2011  91,755 euro/2014  70,754 euro

ATC code B01AC06; 2011  8,957,006 DDD/2014  12,843,360 DDD; 2011  529,577 euro/2014  559,528 euro


### Table S1 Costs used and utility values used in the cost-effectiveness analysis

<table>
<thead>
<tr>
<th>Condition</th>
<th>2015 costs (EUR)</th>
<th>Utility decrement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2015 costs (EUR)</td>
<td>At the time of event</td>
</tr>
<tr>
<td></td>
<td>2015 costs (EUR)</td>
<td>At the time of event</td>
</tr>
<tr>
<td>Fatal cost</td>
<td>Nonfatal cost</td>
<td>Cost</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>2,094.53</td>
<td>3,646.51</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>2,094.53</td>
<td>4,695.21</td>
</tr>
<tr>
<td>Heart failure</td>
<td>2,094.53</td>
<td>3,646.51</td>
</tr>
<tr>
<td>Stroke</td>
<td>2,094.53</td>
<td>5,880.33</td>
</tr>
<tr>
<td>Amputation</td>
<td>7,146.88</td>
<td>7,146.88</td>
</tr>
<tr>
<td>Blindness</td>
<td>1,358.00</td>
<td>1,358.00</td>
</tr>
<tr>
<td>Renal failure</td>
<td>35,071.83</td>
<td>35,071.83</td>
</tr>
<tr>
<td>Ulcer</td>
<td>2,865.00</td>
<td>104.37</td>
</tr>
</tbody>
</table>

| Cost in the absence of complications | |
|-------------------------------------| 283.40 |

### Reference